John F. Milligan Sells 220,000 Shares of Gilead Sciences, Inc. (GILD) Stock
Gilead Sciences, Inc. (NASDAQ:GILD) insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down $1.70 during trading hours on Wednesday, reaching $71.15. 10,925,301 shares of the company’s stock traded hands, compared to its average volume of 9,364,533. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The firm has a market cap of $93,630.00, a P/E ratio of 7.60, a P/E/G ratio of -1.22 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the previous year, the business earned $2.75 EPS. The company’s revenue was down 13.2% on a year-over-year basis. analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/15/john-f-milligan-sells-220000-shares-of-gilead-sciences-inc-gild-stock.html.
Large investors have recently made changes to their positions in the business. Capital International Investors increased its stake in shares of Gilead Sciences by 86.6% in the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after acquiring an additional 5,205,983 shares during the last quarter. Sanders Capital LLC acquired a new position in shares of Gilead Sciences in the third quarter worth $427,585,000. Skandinaviska Enskilda Banken AB publ increased its stake in shares of Gilead Sciences by 230.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock worth $399,233,000 after acquiring an additional 3,434,450 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after acquiring an additional 2,700,600 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in shares of Gilead Sciences by 84.7% in the third quarter. Ameriprise Financial Inc. now owns 5,505,708 shares of the biopharmaceutical company’s stock worth $446,197,000 after acquiring an additional 2,524,657 shares during the last quarter. 74.62% of the stock is currently owned by institutional investors.
Several equities analysts recently issued reports on GILD shares. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 price objective (up from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 price objective for the company in a report on Friday, July 28th. Redburn Partners began coverage on Gilead Sciences in a report on Wednesday, July 26th. They set a “buy” rating for the company. Finally, BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $84.87.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.